Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 380

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss

Open access
Brock, Penelope R., Maibach, Rudolf, Childs, Margaret, Rajput, Kaukab, Roebuck, Derek, Sullivan, Michael J., Laithier, Véronique, Ronghe, Milind, Dall’Igna, Patrizia, Hiyama, Eiso, Brichard, Bénédicte, Skeen, Jane, Mateos, M. Elena, Capra, Michael, Rangaswami, Arun A., Ansari, Marc, Rechnitzer, Catherine, Veal, Gareth J., Covezzoli, Anna, Brugières, Laurence, Perilongo, Giorgio, Czauderna, Piotr, Morland, Bruce, Neuwelt, Edward A.·2018·New England Journal of Medicine

Abstract

BACKGROUND: Cisplatin chemotherapy and surgery are effective treatments for children with standard-risk hepatoblastoma but may cause considerable and irreversible hearing loss. This trial compared cisplatin with cisplatin plus delayed administration of sodium thiosulfate, aiming to reduce the incidence and severity of cisplatin-related ototoxic effects without jeopardizing overall and event-free survival. METHODS: We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses. The primary end point was the absolute hearing threshold, as measured by pure-tone audiometry, at a minimum age of 3.5 years. Hearing loss was assessed according to the Brock grade (on a scale from 0 to 4, with higher grades indicating greater hearing loss). The main secondary end points were overall survival and event-free survival at 3 years. RESULTS: A total of 109 children were randomly assigned to receive cisplatin plus sodium thiosulfate (57 children) or cisplatin alone (52) and could be evaluated. Sodium thiosulfate was associated with few high-grade toxic effects. The absolute hearing threshold was assessed in 101 children. Hearing loss of grade 1 or higher occurred in 18 of 55 children (33%) in the cisplatin-sodium thiosulfate group, as compared with 29 of 46 (63%) in the cisplatin-alone group, indicating a 48% lower incidence of hearing loss in the cisplatin-sodium thiosulfate group (relative risk, 0.52; 95% confidence interval [CI], 0.33 to 0.81; P=0.002). At a median of 52 months of follow-up, the 3-year rates of event-free survival were 82% (95% CI, 69 to 90) in the cisplatin-sodium thiosulfate group and 79% (95% CI, 65 to 88) in the cisplatin-alone group, and the 3-year rates of overall survival were 98% (95% CI, 88 to 100) and 92% (95% CI, 81 to 97), respectively. CONCLUSIONS: The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival. (Funded by Cancer Research UK and others; SIOPEL 6 ClinicalTrials.gov number, NCT00652132 ; EudraCT number, 2007-002402-21 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1801109

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 380

Metadata

Authors
Brock, P. R., Maibach, R., Childs, M., Rajput, K., Roebuck, D., Sullivan, M. J., Laithier, V., Ronghe, M., Dall’Igna, P., Hiyama, E., Brichard, B., Skeen, J., Mateos, M. E., Capra, M., Rangaswami, A. A., Ansari, M., Rechnitzer, C., Veal, G. J., Covezzoli, A., Brugières, L., Perilongo, G., Czauderna, P., Morland, B., & Neuwelt, E. A.
Venue
New England Journal of Medicine
Published
2018-06-21
Volume
378
Issue
25
Pages
2376-2385
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2809505594
Cited by
380
References
1
FWCI
20.89
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. https://app.cochat.ai/papers/10.1056/nejmoa1801109
The paper
Brock, P. R., Maibach, R., Childs, M., Rajput, K., Roebuck, D., Sullivan, M. J., Laithier, V., Ronghe, M., Dall’Igna, P., Hiyama, E., Brichard, B., Skeen, J., Mateos, M. E., Capra, M., Rangaswami, A. A., Ansari, M., Rechnitzer, C., Veal, G. J., Covezzoli, A., . . . Neuwelt, E. A. (2018). Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1801109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.